

Molecular PCR Summary Lab Report

CLINIC INFORMATION		PATIENT	PATIENT INFORMATION			SPECIMEN INFORMATION	
Name: Address: Provider:	Assurance Pathology Laboratory 2868 Acton Road Suite 207 BIRMINGHAM, AL 35243 Test, Doctor MD	Name: DOB: Phone: 3 Address:	Test, Copia 10/28/2000 (999)999-9999 123 Test St BIRMINGHAM		: M	Lab Accession Number: Date Collected: Date Accessioned: Date Reported: Faxed to:	ASL-12102110174 12/09/21 11:48:00 AM 12/10/2021 12/10/2021 18777966185
Endogen Pathoge	<u>ols</u> Extraction Control ous Positive Control n Positive Control n Negative Control	L ¹ PASS ² PASS	(3) Negative Control contains primers, probe, and enzymes with no DNA/RNA template (4) A "Detected" result indicates the presence of a pathogen (99.99% confidence) above the assa cutoff.				
Tost Po	rformed		et Poculto			Commonts	
Test Pe	erformed	Tes	st Results			Comments	
Test Pe COVID-1		Tes	st Results		Col	Comments lection Type: Nasophary	ngeal Swab
	9		TECTED	Use Authoriza	40:55 PM ation #20		pproved under FDA Emergency
COVID-1	9			Use Authoriza or local public [12/10/21 2:4 PCR needed inversely prop CT level, the	40:55 PM ation #20 c health a 40:55 PM to detect portional greater th	Ilection Type: Nasophary COVID-19 assay reviewed and a 0522. Laboratory will immediately r	amplification cycles of real-time 2 gene sequence. CT values are tin the sample (i.e. the lower the the sample). The reference range
COVID-1 COVID- nCoV_N	9 -19 N1 (CT Value)		31.25	Use Authoriza or local public [12/10/21 2:4 PCR needed inversely prop CT level, the	40:55 PM ation #20 c health a 40:55 PM to detect portional greater th	Ilection Type: Nasophary COVID-19 assay reviewed and ap 0522. Laboratory will immediately r gencies of all positive results. CT value indicates the number of COVID-19, a specific SARS-CoV- to the amount of target nucleic acid a amount of target nucleic acid in	proved under FDA Emergency notify appropriate Federal, State, amplification cycles of real-time 2 gene sequence. CT values are 1 in the sample (i.e. the lower the the sample). The reference range <40 cycles of amplification.
COVID-1 COVID- nCoV_N Test Pe	9 -19 N1 (CT Value)	Lab Result (Qualitative Low/M	31.25	Use Authoriza or local public [12/10/21 2:4 PCR needed inversely prop CT level, the for Assurance	40:55 PM ation #20 c health a 40:55 PM to detect portional greater th e Scientifi	Ilection Type: Nasopharyi COVID-19 assay reviewed and ap 0522. Laboratory will immediately rigencies of all positive results. CT value indicates the number of COVID-19, a specific SARS-CoV- to the amount of target nucleic acid ne amount of target nucleic acid in c Laboratories RT-PCR assays is -	proved under FDA Emergency notify appropriate Federal, State, amplification cycles of real-time 2 gene sequence. CT values are d in the sample (i.e. the lower the the sample). The reference range <40 cycles of amplification.

Clinic Name: Assurance Pathology Laboratory

Lab Director: Ty Thomas, MD

Page: 1

Test results must be evaluated with clinical symptoms to diagnose disease. All tests established and validated by Laboratory and not FDA approved unless otherwise indicated. Methodology statement: Real-time PCR assays are designed to detect pathogens with clinical significance and analytical sensitivity and specificity greater than 99%. Limitations: While these assays are very sensitive and specific, theoretically these assays could detect pathogens not listed, resulting in a false positive. In addition, while these assays are very specific, there may be target pathogen sequences with unknown sequence variability which may not be detected, resulting in a false negative result.



Molecular PCR Summary Lab Report

Sex: M

2868 Acton Road, Suite 207 Birmingham, AL, 35243 Phone: (855) 319-4459 CLIA ID: 01-D2074949

CLINIC INFORMATION

Name:	Assurance Pathology Laboratory
Address:	2868 Acton Road Suite 207 BIRMINGHAM, AL 35243
Provider:	Test, Doctor MD

Name: Test, Copia DOB: 10/28/2000 Se Phone: (999)999-9999 Address: 123 Test St BIRMINGHAM, AL 35243

PATIENT INFORMATION

SPECIMEN INFORMATION

110174
1:48:00 AM
85
1

Test Performed	Lab Result (4) (Qualitative Low/Medium/High)	DNA Copy Number	Comments	
COVID Respiratory Panel		Collection Type: Nasopharyngeal Swab		
Adenovirus	Not Detected	Not Detected	[12/10/21 2:40:55 PM] Assay is developed to detect all strains of this pathogen	
Bocavirus	Not Detected	Not Detected	[12/10/21 2:40:55 PM] Assay is developed to detect all strains of this pathogen	
Bordetella pertussis	Not Detected	Not Detected	[12/10/21 2:40:55 PM] Shares homology with B.holmesii.	
Chlamydophila pneumoniae	DETECTED - MEDIUM	1.00E+03		
Coronavirus HKU1	Not Detected	Not Detected		
Coronavirus 229E	Not Detected	Not Detected		
Coronavirus NL63	Not Detected	Not Detected		
Coronavirus OC43	Not Detected	Not Detected		
EBV (Mononucleosis)	Not Detected	Not Detected		
Enterovirus	Not Detected	Not Detected	[12/10/21 2:40:55 PM] Enterovirus includes Coxsackie virus types A9, A10, A16, B5, and Echovirus serotypes May cross-react with Rhinovirus (types A and B)	
Haemophilus influenzae	Not Detected	Not Detected		
HMPV A (Human Metapneumovirus)	Not Detected	Not Detected		
HMPV B (Human Metapneumovirus)	Not Detected	Not Detected		
Influenza A	Not Detected	Not Detected		
Influenza B	Not Detected	Not Detected		
Moraxella catarrhalis	Not Detected	Not Detected		
Mycoplasma pneumoniae	Not Detected	Not Detected		
Parainfluenza 1	Not Detected	Not Detected		
Parainfluenza 2	Not Detected	Not Detected		
Parainfluenza 3	Not Detected	Not Detected		
Parainfluenza 4	Not Detected	Not Detected		
Rhinovirus (types A & B)	Not Detected	Not Detected	[12/10/21 2:40:55 PM] Assay is developed to detect all strains of this pathogen May cross-react to Enterovirus	
RSV A/B (Respiratory Syncytial Virus)	Not Detected	Not Detected		
Staphylococcus aureus	Not Detected	Not Detected		
Streptococcus pneumoniae	Not Detected	Not Detected		
Streptococcus pyogenes (Group A)	Not Detected	Not Detected		

Clinic Name: Assurance Pathology Laboratory

Patient name: Test, Copia

Lab Director: Ty Thomas, MD

Test results must be evaluated with clinical symptoms to diagnose disease. All tests established and validated by Laboratory and not FDA approved unless otherwise indicated. Methodology statement: Real-time PCR assays are designed to detect pathogens with clinical significance and analytical sensitivity and specificity greater than 99%. Limitations: While these assays are very sensitive and specific, theoretically these assays could detect pathogens not listed, resulting in a false positive. In addition, while these assays are very specific, there may be target pathogen sequences with unknown sequence variability which may not be detected, resulting in a false negative result.